The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis

Enfortumab Vedotin (EV) is FDA-approved for advanced urothelial cancer in patients previously treated with platinum-based chemotherapy and a checkpoint inhibitor. We conducted a real-world study to determine the extent of EV wastage in a single institution and assessed the financial impact of EV was...

Full description

Bibliographic Details
Main Authors: Michal Sarfaty, Assaf Moore, Ashley M. Regazzi, Aaron P. Mitchell, Jonathan E. Rosenberg
Format: Article
Language:English
Published: MDPI AG 2021-11-01
Series:Cancers
Subjects:
enfortumab vedotin
urothelial cancer
drug wastage
vial size
Online Access:https://www.mdpi.com/2072-6694/13/23/5977

Internet

https://www.mdpi.com/2072-6694/13/23/5977

Similar Items